NCT03916744 - A Study of Giredestrant (GDC-9545) in Postmenopausal Women With Stage I-III Operable, Estrogen Receptor-Positive Breast Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 26, 2019

Primary Completion Date

May 25, 2021

Study Completion Date

May 25, 2021

Conditions

Breast Cancer

Interventions

DRUG

Giredestrant

Giredestrant will be administered orally once daily (QD) starting on Day 1 up to and including the day of surgery (if allowed per local process) on Day 15 (+/-2 days).

PROCEDURE

Surgery

Breast cancer surgery will take place on Day 15 (+/-2 days).

Trial Locations (15)

1160

Clinique Edith Cavell; Pharmacie, Auderghem

2010

St Vincent's Hospital Sydney, Darlinghurst

2650

UZ Antwerpen, Edegem

3021

Sunshine Hospital, St Albans

5000

Clinique Sainte-Elisabeth; Oncologie, Namur

10065

Memorial Sloan Kettering Cancer Center, New York

20014

Onkologikoa - Instituto Oncológico de Donostia, Donostia / San Sebastian

28034

Hospital Ruber Internacional;Servicio de Oncologia, Madrid

28050

HM Sanchinarro ? CIOCC, Madrid

46010

Hospital Clinico Universitario de Valencia, Valencia

80045-2517

University of Colorado, Aurora

02114

Massachusetts General Hospital, Boston

08035

Hospital Universitari Vall d'Hebron, Barcelona

EC1M 6BQ

Barts Health NHS Trust; William Harvey Heart Centre, QMUL School of Medicine & Dentistry, London

TR1 3LQ

Royal Cornwall Hospital, Truro